Efficacy, safety and prognostic factors in patients with refractory metastatic colorectal cancer treated with trifluridine/tipiracil plus bevacizumab in a real-world setting

Nieves Martínez-Lago1*, Teresa Calleja Chucla2, Beatriz Alonso De Castro1, Rafael Varela Ponte3, Cristina Reboredo Rendo1, Martin Igor Gomez-Randulfte Rodríguez1, Sofía Silva Díaz2, Begoña Graña Suárez1, Juan de la Cámara Gomez1, Fernando Busto Fernández2, María Mateos Salvador2 & Margarita Reboredo Lopez1

We evaluated the efficacy and safety of trifluridine/tipiracil (TAS-102) plus bevacizumab in treating refractory metastatic colorectal cancer (mCRC) in a retrospective, observational study. Patients refractory or intolerant to standard therapies received TAS-102 (30–35 mg/m² twice daily on days 1–5 and days 8–12 every 28 days) plus bevacizumab 5 mg/kg on days 1 and 15. Clinical and pathological characteristics, overall response rate (ORR), disease control rate (DCR), overall survival (OS) and progression-free survival (PFS) data were collected and analysed. Thirty-five patients were treated from July 2019 to October 2021 (median age 64 years). The majority of patients (68.6%) were receiving TAS-102 plus bevacizumab as third-line treatment. Patients received a median of 4 (range 2–15) cycles of treatment. Among 31 patients evaluable for response (88.6%), ORR and DCR were 3.2% and 51.6%, respectively. After a median 11.6 months’ follow-up, median PFS was 4.3 (95% confidence interval [CI] 3.4–5.1) months and median OS was 9.3 (95% CI 6.6–12.1) months. The most common grade 3–4 toxicities were neutropenia, asthenia and nausea/vomiting, and there were no treatment-related deaths. This real-world study confirms the efficacy and safety of TAS-102 plus bevacizumab in patients with refractory mCRC.

Colorectal cancer (CRC) is the second highest cause of cancer-related death worldwide, with an estimated 1.8 million new cases and > 880,000 deaths in 20181. Evidence-based guidelines recommend cytotoxic chemotherapy (e.g. oxaliplatin, irinotecan or fluoropyrimidines) as first- and second-line treatment in patients with metastatic CRC (mCRC), with the addition of anti-epidermal growth factor receptor (EGFR) agents (i.e. cetuximab or panitumumab) in those with wild-type RAS tumours or the anti-vascular endothelial growth factor (VEGF) agent bevacizumab2. However, a high proportion of patients develop progressive disease (PD) after receiving standard chemotherapy, with > 40% receiving at least three lines of treatment3. Treatment recommendations now include the multi-kinase inhibitor regorafenib and trifluridine/tipiracil (TAS-102) as third-line treatment options in these patients.

The efficacy and safety of TAS-102, a combination of a thymidine-based nucleic acid analogue (trifluridine) and a thymidine phosphorylase inhibitor (tipiracil), have been demonstrated in clinical studies of patients with previously treated mCRC, with significantly improved overall survival (OS) compared with placebo4,5. An exploratory analysis of the RECORCE clinical study6 identified patients with low tumour burden and less...
aggressive disease (i.e. ≥ 18 months since metastatic disease diagnosis) as having improved survival outcomes with TAS-102 monotherapy.

The survival benefits with TAS-102 monotherapy are modest and there is a need for improved treatment options in patients with refractory mCRC. Several phase I/II and phase II studies have investigated the efficacy and safety of TAS-102 in combination with bevacizumab. These studies included the single-arm Japanese C-TASK FORCE study in 25 patients with refractory mCRC, which reported a centrally-assessed median progression-free survival (PFS) of 3.7 months and a median OS of 11.4 months with TAS-102 plus bevacizumab. In a Danish randomised study in 93 patients with refractory mCRC, TAS-102 plus bevacizumab was associated with significantly improved median PFS (4.6 vs 2.6 months, hazard ratio [HR] 0.45, p = 0.001) and median OS (9.4 vs 6.7 months, HR 0.55, p = 0.028) compared with TAS-102 monotherapy.

Previous retrospective studies of Japanese patients with refractory mCRC have also indicated that the TAS-102 plus bevacizumab combination provides significant survival benefits compared with TAS-102 monotherapy in routine clinical practice; however, real-world data on the use of TAS-102 plus bevacizumab in non-Asian populations are limited. The aim of this real-world study was to evaluate the efficacy, safety and prognostic factors of TAS-102 plus bevacizumab in patients with refractory mCRC in routine clinical practice in Spain.

Results
Population characteristics. Thirty-five patients were treated with TAS-102 plus bevacizumab between July 2019 and October 2021 and were included in this study. Patient characteristics are summarised in Table 1. Patients had a median (range) age of 65 (41–82) years and 31.4% were aged ≥ 70 years. The majority of patients (94.3%) had undergone primary tumour resection, 80.0% had liver metastases, and 71.4% were diagnosed with metastatic disease ≥ 18 months before starting TAS-102 plus bevacizumab. Previous treatment included anti-VEGF therapy in 88.6% of patients (bevacizumab in 57.1% patients, aflibercept in 8.6%, or both bevacizumab and aflibercept in 28.6% of patients); 68.6% were receiving TAS-102 plus bevacizumab as third-line treatment. None of the patients had previously received regorafenib.

TAS-102 was started at a reduced dose (30 mg/m²) in seven patients (20.0%) and no patients started bevacizumab at reduced doses. Prophylactic granulocyte colony-stimulating factor (G-CSF) treatment was administered in C-TASK FORCE (11.4 months) and the Danish study (9.4 vs 6.7 months, HR 0.55, p = 0.028) compared with TAS-102 monotherapy.

The efficacy of TAS-102 plus bevacizumab in our study was also generally comparable with that reported in previous real-world retrospective studies of Japanese patients with refractory mCRC, in which the median PFS with TAS-102 plus bevacizumab was 3.7 months or 4.4 months, and the median OS ranged from 8.6 to 14.4 months. Patients with refractory mCRC often have poor prognosis. In our real-world study, 22.9% of patients had an ECOG PS of 2 and therefore may be less representative of patients with refractory mCRC in routine clinical practice than the previous C-TASK FORCE and Danish clinical studies, which excluded patients with ECOG PS of 2.
with ECOG PS of 2 (or modified Glasgow prognostic score of 2) was also much lower (1.4–4.8%) than in our study. Therefore, our study indicates that TAS-102 plus bevacizumab continues to be effective in patients with refractory mCRC and poor performance status scores.

In the univariate analysis of prognostic factors for survival, our study showed that OS and PFS were significantly improved in patients without peritoneal metastases, and those with low tumour histological grade had significantly improved OS. However, patients with low tumour burden (< 3 metastatic sites) had significantly worse PFS compared with those with ≥ 3 metastatic sites. Although this result seems counterintuitive, the low

| Characteristics                             | N = 35 |
|---------------------------------------------|--------|
| Age, years                                  |        |
| Median (range)                              | 65 (41–82) |
| ≥70 years, n (%)                            | 11 (31.4) |
| Gender, n (%)                               |        |
| Male                                        | 22 (62.9) |
| Female                                      | 13 (37.1) |
| ECOG PS, n (%)                              |        |
| 0–1                                         | 27 (77.1) |
| 2                                           | 8 (22.9) |
| Tumour location, n (%)                      |        |
| Right-sided                                 | 4 (11.4) |
| Left-sided                                  | 17 (48.6) |
| Rectum                                      | 14 (40.0) |
| Histological grade, n (%)                   |        |
| Low grade (G1–G2)                           | 22 (62.9) |
| High grade (G3)                             | 2 (5.7) |
| Unknown                                     | 11 (31.4) |
| RAS/BRAF mutational status, n (%)           |        |
| RAS/BRAF wild type                          | 16 (45.7) |
| RAS mutated                                 | 17 (48.6) |
| BRAF mutated                                | 2 (5.7) |
| Mismatch repair protein expression, n (%)   |        |
| Conserved                                   | 35 (100) |
| Tumour presentation, n (%)                  |        |
| Synchronous                                 | 23 (65.7) |
| Metachronous                                | 12 (34.3) |
| Primary tumour surgery, n (%)               | 31 (88.6) |
| Previous anti-VEGF therapy, n (%)           | 33 (94.3) |
| Bevacizumab, %                              | 57.1 |
| Aflibercept, %                              | 8.6 |
| Both, %                                     | 28.6 |
| Line of TAS-102 + bevacizumab treatment, n (%) |        |
| 3                                           | 24 (68.6) |
| 4                                           | 4 (11.4) |
| ≥ 5                                         | 7 (20.0) |
| Liver metastases, n (%)                     | 28 (80.0) |
| No. of metastatic locations, n (%)          |        |
| < 3                                         | 22 (62.9) |
| ≥ 3                                         | 13 (37.2) |
| Time from metastatic disease diagnosis, n (%) |        |
| < 18 months                                 | 10 (28.6) |
| ≥ 18 months                                 | 25 (71.4) |
| Tabernero prognostic classification, n (%)  |        |
| Best                                        | 3 (8.6) |
| Good                                        | 12 (34.3) |
| Poor                                        | 20 (57.1) |

Table 1. Study population characteristics. ECOG PS Eastern Cooperative Oncology Group performance status, G grade, No. number, TAS-102 trifluridine/tipiracil, VEGF vascular endothelial growth factor.
tumour burden may be an indicator of treatment intensity or the finding may be a statistical artefact associated with the small population size of our study. Another study found no difference in survival outcomes between patients CRC with three versus four metastatic sites\textsuperscript{18}. Moreover, a large database analysis of the correlates of survival showed that the organ affected by metastasis was an important determinant of survival\textsuperscript{19}. Further research is needed to determine whether it is the number of metastatic sites or the organs affected by metastases that has the greatest impact on survival outcomes.

Previous studies have identified other baseline prognostic factors associated with improved clinical outcomes with TAS-102 (either as monotherapy or combined with bevacizumab), including modified Glasgow prognostic score\textsuperscript{20}, the ‘Tabernero prognostic factors’ [i.e. low tumour burden, less aggressive disease (≥ 18 months since diagnosis of metastatic disease) and liver metastases]\textsuperscript{17}. However, our study did not identify liver metastases or the time since diagnosis of metastasis < 18 months (i.e. the Tabernero factors) as being prognostic of OS or PFS, and we did not examine mutational status, CEA or ALP levels, or lymphocyte-to-monocyte or neutrophil-to-lymphocyte ratios as potential prognostic factors.

In our study, TAS-102 plus bevacizumab was associated with manageable toxicities, with the most common grade 3–4 AEs being neutropenia, asthenia and nausea/vomiting. The incidence of grade 3–4 neutropenia (45.7%) was lower than that reported in the C-TASK FORCE study (72%)\textsuperscript{9} and the Danish study (67%)\textsuperscript{10}, and was slightly lower than in previous Japanese real-world studies (48.2–52.4%)\textsuperscript{14–16}. Furthermore, no patients developed febrile neutropenia in our study, while the incidence of this event was 16% and 6%, respectively, in C-TASK FORCE and the Danish study\textsuperscript{9,10}, and 0–3.3% in the Japanese real-world studies\textsuperscript{14–16}. The lower levels of haematological toxicity observed in our study may have been due to the relatively high proportion of patients who received prophylactic G-CSF therapy (14.3%). Of note, several studies have reported that chemotherapy-induced neutropenia with TAS-102 (with or without bevacizumab) is associated with improved survival outcomes\textsuperscript{22–24}, which highlights the importance of G-CSF prophylaxis to prevent or manage neutropenia and allow for continued TAS-102 plus bevacizumab treatment without the need for dose reduction.

The limitations of our study include its retrospective, single-arm, single-centre design and its small population size (N = 35). An ongoing international phase III study (SUNLIGHT; NCT04737187) is currently investigating the efficacy and safety of TAS-102 plus bevacizumab versus TAS-102 monotherapy as third-line treatment in patients with refractory mCRC, and has a target enrolment of 490 patients\textsuperscript{25}. This open-label, multicentre study aims to further confirm the clinical benefits of TAS-102 plus bevacizumab over TAS-102 monotherapy in a large population of patients with refractory mCRC; results are expected in 2023.

In conclusion, this real-world study confirms the efficacy and safety of TAS-102 plus bevacizumab in patients with refractory mCRC in routine clinical practice, with survival and tolerability outcomes that were generally consistent with previous clinical and real-world studies of patients in this setting.

### Methods

#### Study design.

This observational, retrospective, single-centre study was conducted at the A Coruña University Hospital in Spain in patients aged > 18 years with a confirmed diagnosis of mCRC who were refractory or intolerant to standard therapies. Previous treatment included fluoropyrimidine, oxaliplatin and irinotecan-based chemotherapy and anti-EGFR agents (in patients with wild-type RAS/BRAF tumours). Eligible patients had received treatment with TAS-102 plus bevacizumab in routine clinical practice between July 2019 and October 2021, including patients who had previously received treatment with antiangiogenic agents (i.e. bevacizumab and/or aflibercept). Patients who had previously received TAS-102 monotherapy or TAS-102 in combination with antiangiogenic agents other than bevacizumab were excluded.

The standard doses administered at A Coruña University Hospital were TAS-102 30–35 mg/m\(^2\) on days 1–5 and days 8–12 every 28 days plus bevacizumab 5 mg/kg every 14 days. Starting treatment with reduced doses of TAS-102 or administration of prophylactic G-CSF was at the discretion of the treating physician.

The study was approved by the local ethics committee and conducted in accordance with the Declaration of Helsinki. All patients gave their informed consent prior to study inclusion.

### Table 2. Response rate. CR complete response, DCR disease control rate, ORR overall response rate, PD progressive disease, PR partial response, SD stable disease.

| Response, n (%) | N=31 |
|----------------|------|
| CR             | 0    |
| PR             | 1 (3.2) |
| SD             | 15 (48.4) |
| PD             | 15 (48.4) |
| ORR (CR + PR)  | 1 (3.2) |
| DCR (CR + PR + SD) | 16 (51.6) |
Data collection. Clinical pathological characteristics and treatment data were collected from eligible patients’ medical records, including sex, age and ECOG PS. Disease characteristics included RAS and BRAF mutational status, mismatch repair protein expression, primary tumour location, histological grade, tumour presentation (synchronous or metachronous), the number of metastatic locations (< 3 or ≥ 3), the interval from metastatic disease diagnosis to TAS-102 plus bevacizumab initiation (≥ 18 or < 18 months), and the Tabernero prognostic classification (best, good or poor)⁷, as well as treatment history, including primary tumour resection, metastatic disease resection and previous treatments received. The start date and initial doses of TAS-102 plus bevacizumab, the use of prophylactic G-CSF, the number of cycles received, the response obtained (assessed by Response Evaluation Criteria in Solid Tumors version 1.1 criteria), disease progression and/or survival, toxicities

Figure 1. Kaplan–Meier curves for (a) progression-free survival (PFS) and (b) overall survival (OS).
### Table 3. Univariate analysis of prognostic factors for progression-free and overall survival.

| Characteristic                        | PFS, months | HR (95% CI)* | p-value* | OS, months | HR (95% CI)* | p-value* |
|---------------------------------------|-------------|--------------|----------|------------|--------------|----------|
| Gender                                |             |              |          |            |              |          |
| Male                                  | 4.2         | 1.233 (0.6–2.7) | 0.599    | 8.1        | 1.186 (0.5–2.9) | 0.704 |
| Female                               | 4.7         | –            | –        | 11.1       | –            | –        |
| ECOG PS                               |             |              |          |            |              |          |
| 0–1                                   | 4.7         | 0.652 (0.3–1.6) | 0.336    | 9.3        | 0.517 (0.2–1.4) | 0.182 |
| 2                                    | 3.5         | –            | –        | 8.1        | –            | –        |
| Histological grade                    |             |              |          |            |              |          |
| G1–G2                                 | 4.7         | 0.424 (0.1–1.9) | 0.247    | 10.6       | 0.087 (0.1–0.5) | 0.001 |
| G3                                   | 2.5         | –            | –        | 3.4        | –            | –        |
| Tumour presentation                   |             |              |          |            |              |          |
| Synchronous                           | 4.0         | 2.391 (0.9–5.7) | 0.053    | 9.3        | 1.017 (0.4–2.6) | 0.971 |
| Metachronous                          | 6.0         | –            | –        | 10.6       | –            | –        |
| Tumour surgery                        |             |              |          |            |              |          |
| No                                    | 2.8         | 1.044 (0.4–3.0) | 0.837    | 5.3        | 1.396 (0.5–4.3) | 0.562 |
| Yes                                   | 4.3         | –            | –        | 9.3        | –            | –        |
| Metastatic sites                      |             |              |          |            |              |          |
| <3                                    | 3.0         | 2.286 (1.0–5.1) | 0.001    | 5.2        | 2.790 (0.9–7.8) | 0.06  |
| ≥3                                   | 8.2         | –            | –        | 17.7       | –            | –        |
| Liver metastases                      |             |              |          |            |              |          |
| No                                    | 17.5        | 0.309 (0.1–1.1) | 0.069    | 8.1        | 0.782 (0.2–2.7) | 0.696 |
| Yes                                   | 4.0         | –            | –        | 9.3        | –            | –        |
| Peritoneal metastases                 |             |              |          |            |              |          |
| No                                    | 4.7         | 0.393 (0.1–0.9) | 0.046    | 9.3        | 0.437 (0.2–1.0) | 0.07  |
| Yes                                   | 2.8         | –            | –        | 5.6        | –            | –        |
| Time from metastatic disease diagnosis|             |              |          |            |              |          |
| ≥18 months                            | 4.3         | 0.763 (0.3–1.8) | 0.523    | 9.3        | 0.871 (0.3–2.3) | 0.780 |
| < 18 months                           | 4.8         | –            | –        | 17.7       | –            | –        |
| Tabernero prognostic classification   |             |              |          |            |              |          |
| Best                                  | NR          | –            | 0.069    | NR         | –            | 0.071   |
| Good                                  | 5.0         | –            | –        | 11.1       | –            | –        |
| Poor                                  | 3.5         | –            | –        | 7.9        | –            | –        |

*Significant values are indicated in bold text.

### Table 4. Summary of the most frequent all grade and grade 3/4 adverse events.

| AE, n (%) | All grades | Grade 3–4 |
|-----------|------------|-----------|
| Neutropenia | 26 (74.3) | 16 (45.7) |
| Asthenia | 23 (65.7) | 6 (17.1) |
| Anaemia | 17 (54.8) | 2 (5.7) |
| Thrombocytopenia | 12 (34.3) | 2 (5.7) |
| Diarrhoea | 12 (34.3) | 2 (5.7) |
| Hepatic function abnormalities | 8 (22.9) | 0 |
| Nausea/vomiting | 6 (17.1) | 3 (8.6) |
| Bleeding | 4 (11.4) | 0 |
| Hypertension | 2 (5.7) | 1 (2.9) |
| Venous thromboembolism | 0 | 0 |
| Febrile neutropenia | 0 | 0 |

AE adverse event.
according to Common Terminology Criteria for Adverse Events version 4.0, and any dose delays and/or dose reductions were also collected retrospectively from patient records for analysis.

**Study assessments.** OS was defined as the time between treatment initiation and death from any cause. PFS was defined as the interval between treatment initiation and radiological confirmation of disease progression or death from any cause. The ORR was defined as the proportion of patients who achieved CR or PR; the DCR was defined as the proportion of patients who achieved CR, PR, or stable disease for ≥6 weeks after treatment initiation.

**Statistical analyses.** Statistical analyses were performed using SPSS statistics software version 25.0. The Chi-squared or Fisher’s exact test (depending on the sample size) was used to compare patient clinical and demographic variables. The Kaplan–Meier model was used to estimate median PFS and OS and their 95% CIs. An analysis of potential predictors of PFS or OS was also conducted by comparing the differences between survival curves using univariate logistic regression and the log-rank test with a two-sided significance of <0.05.

**Institutional review board statement.** Approved by Clinical Research Ethics Committee (CEIC) of Galicia, Spain.

**Data availability**
All data are available upon request from the corresponding author.

Received: 11 January 2022; Accepted: 22 August 2022
Published online: 26 August 2022

**References**
1. Bray, F. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424. https://doi.org/10.3322/caac.21492 (2018).
2. Van Cutsem, E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann. Oncol. 27, 1386–1422. https://doi.org/10.1093/annonc/mdw235 (2016).
3. Carlomagno, C. et al. Multiple treatment lines and prognosis in metastatic colorectal cancer patients. Cancer Metastasis Rev. 38, 307–313. https://doi.org/10.1007/s10555-018-9748-7 (2019).
4. Mayer, R. J. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N. Engl. J. Med. 372, 1909–1919. https://doi.org/10.1056/NEJMoa1414325 (2015).
5. Xu, J. et al. Results of a randomized, double-blind, placebo-controlled, phase III trial of trifluridine/tipiracil (TAS-102) monotherapy in Asian patients with previously treated metastatic colorectal cancer: The TERRA study. J. Clin. Oncol. 36, 350–358. https://doi.org/10.1200/JCO.2017.74.3245 (2018).
6. Yoshino, T. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: A double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol. 13, 993–1001. https://doi.org/10.1016/S1470-2045(12)70345-5 (2012).
7. Tabernero, J. et al. Effect of trifluridine/tipiracil in patients treated in RECOVERSE by prognostic factors at baseline: An exploratory analysis. ESMO Open 5, e000752. https://doi.org/10.1136/esmoopen-2020-000752 (2020).
8. Ishizaki, T. et al. Prospective multicenter phase II study of biweekly TAS-102 and bevacizumab for metastatic colorectal cancer. Anticancer Res. 41, 2157–2163. https://doi.org/10.21873/anticancer.14988 (2021).
9. Kuboki, Y. et al. TAS-102 plus bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (C-TASK FORCE): An investigator-initiated, open-label, single-arm, multicentre, phase 1/2 study. Lancet Oncol. 18, 1172–1181. https://doi.org/10.1016/S1470-2045(17)30425-4 (2017).
10. Pfeiffer, P. et al. TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: An investigator-initiated, open-label, randomised, phase 2 trial. Lancet Oncol. 21, 412–420. https://doi.org/10.1016/S1470-2045(19)30827-7 (2020).
11. Satake, H. et al. Phase IIb/III study of biweekly TAS-102 in combination with bevacizumab for patients with metastatic colorectal cancer refractory to standard therapies (BITS Study). Oncologist 25, e1855–e1863. https://doi.org/10.1634/theoncologist.2020-0643 (2020).
12. Takahashi, T. et al. Phase II study of trifluridine/tipiracil plus bevacizumab by RAS mutation status in patients with metastatic colorectal cancer refractory to standard therapies: JFMC51-1702-C7. Lancet Oncol. 2021. 100093. https://doi.org/10.1016/j.esmoop.2021.100093 (2021).
13. Yoshida, Y. et al. Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study. Int. J. Clin. Oncol. 26, 111–117. https://doi.org/10.1007/s10147-020-01794-8 (2021).
14. Chida, K. et al. Efficacy and safety of trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil or regorafenib monotherapy for chemorefractory metastatic colorectal cancer: A retrospective study. Ther. Adv. Med. Oncol. 13, 17588359211009144. https://doi.org/10.1177/17588359211009144 (2021).
15. Fuji, H. et al. Bevacizumab in combination with TAS-102 improves clinical outcomes in patients with refractory metastatic colorectal cancer: A retrospective study. Oncologist 25, e469–e476. https://doi.org/10.1634/theoncologist.2019-0541 (2020).
16. Kotani, D. et al. Retrospective cohort study of trifluridine/tipiracil (TAS-102) plus bevacizumab versus trifluridine/tipiracil monotherapy for metastatic colorectal cancer. BMC Cancer 19, 1253. https://doi.org/10.1186/s12885-019-6475-6 (2019).
17. Fernández Montes, A. et al. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: Real-world vs clinical trial data. Sci. Rep. 11, 14321. https://doi.org/10.1038/s41598-021-93732-5 (2021).
18. Yang, L. et al. Comparisons of metastatic patterns of colorectal cancer among patients by age group: A population-based study. Aging 10, 4077–4119. https://doi.org/10.18632/aging.101700 (2018).
19. Wang, J. et al. Metastatic patterns and survival outcomes in patients with stage IV colon cancer: A population-based analysis. Cancer Med. 9, 361–373. https://doi.org/10.1002/cam4.2673 (2020).
20. Matsuhashi, N. et al. Combination chemotherapy with TAS-102 plus bevacizumab in salvage-line treatment of metastatic colorectal cancer: A single-center, retrospective study examining the prognostic value of the modified Glasgow Prognostic Score in salvage-line therapy of metastatic colorectal cancer. Mol. Clin. Oncol. 11, 390–396. https://doi.org/10.3892/mco.2019.1899 (2019).
21. Kuramochi, H. et al. The pre-treatment lymphocyte-to-monocyte ratio predicts efficacy in metastatic colorectal cancer treated with TAS-102 and bevacizumab. Anticancer Res. 41, 3131–3137. https://doi.org/10.21873/anticancer.15098 (2021).
22. Kasi, P. M. et al. Chemotherapy induced neutropenia at 1-month mark is a predictor of overall survival in patients receiving TAS-102 for refractory metastatic colorectal cancer: A cohort study. *BMC Cancer* **16**, 467. https://doi.org/10.1186/s12885-016-2491-y (2016).

23. Nose, Y. et al. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: A retrospective study. *Cancer Chemother. Pharmacol.* **86**, 427–433. https://doi.org/10.1007/s00280-020-04129-6 (2020).

24. Yoshino, T. et al. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOUROSE and J003 trials. *Ann. Oncol.* **31**, 88–95. https://doi.org/10.1016/j.annonc.2019.10.005 (2020).

25. Tabernero, J. et al. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design. *Future Oncol.* **17**, 1977–1985. https://doi.org/10.2217/fon-2020-1238 (2021).

Acknowledgements

We would like to thank Sarah Greig, PhD, of Springer Healthcare Communications who provided editorial assistance in preparing the first draft of the manuscript. This medical writing assistance was funded by Fundación Profesor Novoa Santos.

Author contributions

N.M.L. contributed to study design, data analysis and drafting of the manuscript. All authors (N.M.L., T.C.C., B.A.D.C., R.V.P., C.R.R., M.I.G.-R.R., S.S.D., B.G.S., J. d.l.C.G., F.B.L., M.M.S. and M.R.L.) enrolled patients, collected clinical information, evaluated study data and critically reviewed the manuscript.

Funding

Biomedical Research Institute of A Coruña.

Competing interests

The authors declare no competing interests.

Additional information

Correspondence and requests for materials should be addressed to N.M.-L.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022